N-Sulfo-glucosamine potassium salt
[CAS# 31284-96-5]

Identification

• Classification: API >> Water, electrolyte and acid-base balance regulator >> Glucose drug
• Name: N-Sulfo-glucosamine potassium salt
• Synonyms: 2-Deoxy-2-sulfoamino-D-glucose potassium salt; 2-Deoxy-2-(sulfoamino)-D-glucose monopotassium salt
• Molecular Formula: C₆H₁₂NKO₈S
• Molecular Weight: 297.32
• CAS Registry Number: 31284-96-5
• EC Number: 608-599-6
• SMILES: C([C@H]([C@H]([C@@H]([C@H](C=O)NS(=O)(=O)[O-])O)O)O)O.[K+]

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302
• Safety Statements: P280-P305+P351+P338

Discovery and Applications

N-Sulfo-glucosamine potassium salt is a chemical compound that belongs to a class of molecules known as glycosaminoglycans (GAGs), which are polysaccharides with important roles in biological systems. The compound is a derivative of glucosamine, a naturally occurring amino sugar that is an essential component of cartilage and connective tissues. The N-sulfo group in N-sulfo-glucosamine potassium salt represents a sulfate group attached to the nitrogen atom of the glucosamine molecule. This modification provides the compound with unique properties compared to its parent compound, glucosamine.

The discovery of N-sulfo-glucosamine potassium salt is part of ongoing research into the chemical modification of glucosamine derivatives, which aim to improve the functional properties of the compound for use in medical and pharmaceutical applications. Sulfation of glucosamine has been shown to enhance its biological activity, particularly in the context of cartilage repair and joint health. Sulfated glucosamine derivatives, including N-sulfo-glucosamine potassium salt, have attracted attention for their potential use in the treatment of osteoarthritis and other joint-related conditions due to their ability to mimic the natural structures found in joint cartilage.

In terms of application, N-sulfo-glucosamine potassium salt has been primarily investigated for its role in the treatment of osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage. It is believed that sulfated glucosamine derivatives can promote the synthesis of glycosaminoglycans and proteoglycans, which are key structural components of cartilage. By enhancing the production of these molecules, N-sulfo-glucosamine potassium salt may help to slow the progression of cartilage degradation in patients with osteoarthritis. Some studies have suggested that sulfated glucosamine derivatives have better bioavailability and effectiveness compared to non-sulfated glucosamine, making them promising candidates for therapeutic use in joint disorders.

Furthermore, the compound has been explored in the context of drug delivery systems, where its unique chemical structure can be used to modify the release profiles of drugs. The sulfate group in N-sulfo-glucosamine potassium salt can potentially interact with various biological molecules, enhancing the compound’s ability to deliver drugs in a controlled manner, particularly in tissues involved in inflammatory responses, such as joints.

In addition to its potential applications in osteoarthritis and drug delivery, N-sulfo-glucosamine potassium salt is of interest for its role in the synthesis of more complex glycosaminoglycan derivatives, which have broader biological and pharmaceutical uses. Research into sulfated glucosamine derivatives continues, particularly in the areas of tissue engineering and regenerative medicine, where they may contribute to the development of biomaterials that mimic the natural extracellular matrix.

In summary, N-sulfo-glucosamine potassium salt is a chemically modified derivative of glucosamine with potential applications in the treatment of osteoarthritis, drug delivery, and tissue engineering. Its sulfated structure confers properties that enhance its biological activity, particularly in cartilage repair, and ongoing research continues to explore its utility in various medical fields. The compound exemplifies the role of modified natural products in advancing therapeutic strategies for musculoskeletal diseases and beyond.

References

none